The development of direct oral anticoagulants (DOACs) has advanced the therapeutic landscape for the management of thromboembolic events. Specific agents that rapidly reverse the effects of DOACs are now available and offer safe and effective options for patients who experience an emergency DOAC-associated bleeding event. This interactive activity will offer clinical pearls for the assessment of bleeding severity in patients receiving DOACs; expert-guided insights to rapid reversal of urgent DOAC-associated bleeding; and clinical decision support tools to optimize outcomes in patients requiring reversal of DOACs.
To access this activity, click here:
